The in vitro susceptibility of 14 European Chlamydia psittaci strains from turkeys to the antibiotics doxycycline and enrofloxacin was tested. For doxycycline the MIC ranged from 0.05 to 0.2 g/ml, with an average of 0.1 g/ml. For enrofloxacin the MIC was 0.25 g/ml. Acquired resistance was not detected against doxycycline and enrofloxacin.
Chlamydia psittaci infections in turkeys are frequently diagnosed (3, 14) . C. psittaci is a well-known zoonotic agent which has been shown to spread from turkeys to humans (3) . In human medicine, doxycycline and some fluoroquinolones are recommended for the treatment of Chlamydia trachomatis infections (15) . For the treatment of Chlamydia pneumoniae infections in humans, doxycycline is effective (4) . The antibiotics of choice in veterinary medicine for the treatment of C. psittaci infections are doxycycline or other tetracyclines and the fluoroquinolone enrofloxacin (2) . Resistance of Chlamydia species to tetracyclines has been reported in human and veterinary medicine in only a few cases (8, 9) .
To our knowledge, the in vitro susceptibilities of C. psittaci strains from turkeys to doxycycline and enrofloxacin have not been reported previously. It was the purpose of the present study to determine the MICs of doxycycline and enrofloxacin against a series of C. psittaci isolates collected from field infections in turkeys in Europe.
Buffalo Green monkey cells (kidney cells from the Buffalo Green monkey) were used for in vitro culturing of C. psittaci and for MIC determinations. Cells were grown as described before (13) . The cells were subcultured for at least two passages in medium without antibiotics prior to use in determining the MICs of the antibiotics, as described below. The 14 C. psittaci strains (1 Dutch, 2 Italian, and 11 Belgian) were obtained from field infections in commercial turkey flocks by using a sampling and isolation technique described elsewhere (13) . Doxycycline (Alpha Pharma, Zwevegem, Belgium) and enrofloxacin (Bayer, Leverkusen, Germany) solutions were prepared freshly on each testing occasion. The tested dilutions of doxycycline and enrofloxacin ranged from 0.2 to 0.00625 g/ml and from 1 to 0.03125 g/ml, respectively. Titration of the C. psittaci strains was done as described by Vanrompay et al. (13) . MIC determination assays were performed according to the method of Henning and Krauss (6) .
Both doxycycline and enrofloxacin were effective antimicrobial agents for in vitro inhibition of C. psittaci strains from turkeys. The MIC range for doxycycline was between 0.05 and 0.2 g/ml, with an average of 0.1 g/ml. For enrofloxacin, the MIC for all strains was 0.25 g/ml.
Determination of MICs against obligate intracellular bacteria such as C. psittaci is more difficult than for extracellular bacteria. The methods used are not yet standardized, and results can be influenced by technical differences in performance of the assays (4). One such difference is the inoculum size. However, when inoculum sizes causing no immediate cytopathic effects are tested, no differences in MICs are found for C. trachomatis isolates (12) . The time between inoculation and addition of the antibiotic to the medium is only of importance when doxycycline is added more than 3 h after inoculation of C. psittaci (5) . The use of different Chlamydia detection methods gave only slightly different results (7). MIC results are not influenced by differences in cell cultures, duration of contact with the antibiotics tested, or cell treatments (6) .
In the present studies the method of Henning and Krauss (6) was used for determination of the MICs. In this method, the interval between inoculation of the Chlamydia strains and addition of the antibiotic is less than 3 h, and an inoculum size that does not cause immediate cell lysis is used. The results obtained with doxycycline against C. psittaci strains isolated from turkeys are in accordance with those reported by Henning and Krauss (6) and Kimura et al. (10) , who used a method proposed by the Japanese Society of Chemotherapy for C. psittaci isolates from different birds (other than turkeys) and mammals (0.01 to 0.05 g/ml). They are also comparable to those of most other studies of MICs against C. trachomatis and C. pneumoniae, with MICs for doxycycline ranging from 0.01 to 0.5 g/ml (4). To our knowledge, only four Chlamydia strains have been tested for in vitro susceptibility to enrofloxacin (11) . The results were similar to those reported here.
In the present studies, acquired resistance to doxycycline and enrofloxacin was not detected. This finding is similar to the results of Henning and Krauss (5), who did not detect acquired resistance against doxycycline in 31 avian strains or in 30 mammalian strains of C. psittaci. Only one avian C. psittaci strain, originating from a duck and designated JSD, has been reported as having acquired resistance to multiple antibiotics (8) . Acquired resistance has not been reported for C. pneumoniae and seems to be rare in C. trachomatis (9) .
Although doxycycline has high in vitro activity against C.
psittaci, in vivo experiments in birds indicate that treatment periods of 30 to 45 days are necessary (2) . This long period of treatment is not surprising, since clearance of Chlamydia from the host is highly dependent on host responses, and reinfection from the environment is possible (1). In contrast, for the treatment of C. trachomatis infections in humans, a 7-day treatment with doxycycline is recommended. Failure rates in clinical trials have ranged from 0 to 3% in men and 0 to 8% in women (15) . It seems that doxycycline is more effective in the treatment of human C. trachomatis infections than it is in the treatment of C. psittaci infections in birds, although the in vitro susceptibility is within the same range. A possible explanation for the better results in humans might be a lower reinfection rate.
In conclusion, both doxycycline and enrofloxacin have strong in vitro antimicrobial activities against C. psittaci strains isolated from turkeys in Europe. Acquired resistance was not detected in the strains tested against doxycycline and enrofloxacin.
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